News from biovaxys technology corp. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 17, 2023, 08:00 ET BIOVAXYS BEAUFTRAGT DIE MAXIM GROUP ALS FINANZBERATER UND INVESTMENTBANKER

Die BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder das „Unternehmen") freut sich bekannt zu geben, dass es die in...

Apr 17, 2023, 08:00 ET BIOVAXYS RETAINS MAXIM GROUP AS FINANCIAL ADVISOR AND INVESTMENT BANKER

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that it has retained New York...

Apr 17, 2023, 08:00 ET Biovaxys conserva a Maxim Group como asesor financiero y banquero de inversión

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" o "Compañía") se complace en anunciar que ha contratado a Maxim Group LLC ...

Apr 17, 2023, 08:00 ET BIOVAXYS RETIENT MAXIM GROUP COMME CONSEILLER FINANCIER ET BANQUIER D'AFFAIRES

BioVaxys Technology Corp. (CSE : BIOV) (FRA : 5LB) (OTCQB : BVAXF) (« BioVaxys » ou la « Société ») a le plaisir d'annoncer qu'elle a retenu les...

Apr 17, 2023, 08:00 ET BIOVAXYS RETAINS MAXIM GROUP AS FINANCIAL ADVISOR AND INVESTMENT BANKER

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that it has retained New York...

Apr 12, 2023, 12:48 ET BIOVAXYS KÜNDIGT DIE ERNENNUNG DES CFO UND VERÄNDERUNGEN IM VORSTAND AN

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder „Unternehmen") freut sich bekannt zu geben, dass Dasha Enenko zum...

Apr 12, 2023, 08:35 ET BIOVAXYS ANNOUNCES APPOINTMENT OF CFO AND BOARD CHANGES

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that Dasha Enenko has been appointed ...

Mar 16, 2023, 08:00 ET BIOVAXYS ERWIRBT UNTERNEHMEN FÜR MANAGEMENT KLINISCHER STUDIEN UND SCHLIESST PRIVATPLATZIERUNG AB

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder „Unternehmen") gab heute die Übernahme von TAETSoftware Corp...

Mar 16, 2023, 08:00 ET BIOVAXYS ACQUIRES CLINICAL STUDY MANAGEMENT COMPANY AND COMPLETES PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") today announced that it has acquired TAETSoftware Corp...

Dec 21, 2022, 19:58 ET BioVaxys et Procare Health signent un accord de distribution aux États-Unis pour le gel Papilocare et les immunocapsules orales

VANCOUVER, Colombie britannique et BARCELONE, Espagne, 21 décembre 2022 /PRNewswire/ - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:...

Dec 21, 2022, 10:47 ET BioVaxys und Procare Health setzen US-Vertriebsvereinbarung für Papilocare Gel und Oral Immunocaps um

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder das „Unternehmen") und Procare Health Iberia („Pro Care Health") mit ...

Dec 19, 2022, 09:46 ET BioVaxys y Procare Health firman un acuerdo de distribución en EE.UU. para Papilocare Gel y Oral Immunocaps

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" o "Compañía") y Procare Health Iberia, de Barcelona, España ("Procare...

Dec 19, 2022, 07:00 ET BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps

VANCOUVER, British Colombia and BARCELONA, Spain, Dec. 19, 2022 /PRNewswire/ - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)...

Dec 19, 2022, 07:00 ET BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps

VANCOUVER, British Colombia and BARCELONA, Spain, Dec. 19, 2022 /PRNewswire/ - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)...

Dec 06, 2022, 23:23 ET Kenneth Kovan, cofondateur, président et directeur des opérations de BioVaxys, fera une présentation à la MedInvest Oncology Investor Conference

BioVaxys Technology Corp. (CSE : BIOV) (FRA : 5LB) (OTCQB : BVAXF) (« BioVaxys » ou la « Société ») a le plaisir d'annoncer que Kenneth Kovan,...

Dec 05, 2022, 14:08 ET Kenneth Kovan, Mitbegründer, Präsident und Geschäftsführer von BioVaxys, hält Vortrag auf der MedInvest Oncology Investor Conference

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder das „Unternehmen") freut sich bekannt zu geben, dass Kenneth Kovan,...

Dec 05, 2022, 10:09 ET Kenneth Kovan, de BioVaxys, participará en la Conferencia de Inversores en Oncología de MedInvest

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" o "Compañía") se complace en anunciar que Kenneth Kovan, cofundador,...

Dec 05, 2022, 08:00 ET BioVaxys Co-Founder, President and Chief Operating Officer Kenneth Kovan to Present at MedInvest Oncology Investor Conference

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that Co-Founder, President & Chief...

Dec 05, 2022, 08:00 ET BioVaxys Co-Founder, President and Chief Operating Officer Kenneth Kovan to Present at MedInvest Oncology Investor Conference

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that Co-Founder, President & Chief...

Dec 02, 2022, 11:31 ET BioVaxys annonce le succès de l'essai de production de son vaccin bihapténisé contre le cancer ovarien

BioVaxys Technology Corp. (CSE : BIOV) (FRA : 5LB) (OTCQB : BVAXF) (« BioVaxys » ou « la Société ») a le plaisir d'annoncer la réussite de l'essai de ...

Dec 02, 2022, 08:56 ET BioVaxys meldet erfolgreiche Testproduktion seines bi-haptenisierten Impfstoffs gegen Eierstockkrebs

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder „Unternehmen") freut sich, die erfolgreiche sterile und...

Dec 02, 2022, 04:35 ET BioVaxys anuncia el éxito de las pruebas de producción de su vacuna bi-haptenizada contra el cáncer de ovario

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" o "Compañía") se complace en anunciar el éxito de la producción de prueba ...

Dec 01, 2022, 08:00 ET BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and...

Dec 01, 2022, 08:00 ET BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and...

Nov 28, 2022, 21:08 ET BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has closed the first tranche ("Tranche...